Press Release

Feb, 05 2024

Revitalizing Solutions: Advanced Approaches and Therapies for Effective Alopecia Treatment and Hair Loss Management

Alopecia treatment addresses hair loss, employing diverse approaches. Topical applications, such as minoxidil, stimulate hair growth by widening blood vessels, while oral medications such as finasteride inhibit hormonal factors contributing to baldness. Surgical interventions such as hair transplants involve grafting healthy follicles to affected areas. Emerging therapies, including platelet-rich plasma (PRP) injections and low-level laser therapy, show promise. Consultation with a dermatologist determines the most suitable treatment, tailored to individual needs and conditions.

Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/north-america-alopecia-treatment-hair-loss-market

Data Bridge Market Research analyzes that the North America Alopecia Treatment (Hair Loss) Market, which was USD 1,947.87 million in 2022, is expected to reach USD 3,081.26 million by 2030, and is expected to undergo a CAGR of 5.90% during the forecast period from 2023 to 2030. The surge in alopecia cases in North America propels demand for effective treatments, emphasizing the crucial role of addressing the increasing prevalence of hair loss through advanced and innovative solutions.

Key Findings of the Study

North America Alopecia Treatment (Hair Loss) Market

Expanding aging population is expected to drive the market's growth rate

The expanding aging population in North America significantly propels the alopecia treatment market, given the common correlation between aging and hair loss. As individuals age, hormonal changes and genetic factors contribute to hair thinning and baldness. This demographic shift creates a heightened demand for effective alopecia treatments, including pharmaceuticals and surgical interventions. The desire to address age-related hair loss concerns drives a substantial market share, prompting continuous research and development to meet the evolving needs of this demographic.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug Type (Minoxidil, Finasteride, Others), Indication (Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, Others), Diagnosis (Trichoscopy, Skin Biopsy, Others), Gender (Male, Female), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America

Market Players Covered

Johnson & Johnson Private Limited (U.S.), GlaxoSmithKline plc (UK), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Ireland), Cipla Inc. (U.S.), Endo International plc (Ireland), Zydus Cadila (India), Abbott (U.S.), Aurobindo Pharma (India), Dr. Reddy’s Laboratories Ltd. (India), Perrigo Company plc (Ireland), Curallux, LLC. (U.S.), DR. KURT WOLFF GMBH & CO. KG (Germany), WOCKHARDT (India)

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The North America alopecia treatment (hair loss) market is segmented on the basis of drug type, indication, diagnosis, gender, route of administration, end-users, and distribution channel.

  • On the basis of drug type, the North America alopecia treatment (hair loss) market is segmented into minoxidil, finasteride and others
  • On the basis of indidcation, the North America alopecia treatment (hair loss) market is segmented into androgenic alopecia, alopecia areata, alopecia totalis, and others
  • On the basis of diagnosis, the North America alopecia treatment (hair loss) market is segmented into trichoscopy, skin biopsy, and others
  • On the basis of gender, the North America alopecia treatment (hair loss) market is segmented into male and female
  • On the basis of route of administration, the North America alopecia treatment (hair loss) market is segmented into oral, topical, parenteral, and others
  • On the basis of end-users, the North America alopecia treatment (hair loss) market is segmented into hospitals, specialty clinics, homecare, and others
  • On the basis of distribution channel, the North America alopecia treatment (hair loss) market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others

Major Players

Data Bridge Market Research recognizes the following companies as the major North America alopecia treatment (hair loss) market players in North America alopecia treatment (hair loss) market are Dr. Reddy’s Laboratories Ltd. (India), Perrigo Company plc (Ireland), Curallux, LLC. (U.S.), DR. KURT WOLFF GMBH & CO. KG (Germany), WOCKHARDT (India)

North America Alopecia Treatment (Hair Loss) Market

Market Developments

  • In 2022, South Korean hair care brand Dr. Groot launched a shampoo containing brewer's yeast, targeting the hair loss market. Claiming to enhance the microbiome, the product aims to address symptoms of hair loss, such as alopecia. This innovation aligns with the ongoing advancements in hair care linked to treatments for alopecia, offering potential solutions for those seeking effective and microbiome-friendly remedies
  • In 2022, UNITE Hair launched BOOSTA PLUS+ Hair serum, aiming to address alopecia by activating stem cells and rejuvenating hair follicles, thus preventing hair loss. This innovative product aligns with advancements in alopecia treatments, showcasing UNITE Hair's commitment to combating hair loss in the dynamic market of hair care solutions
  • In 2021, Pfizer revealed positive top-line results from the phase 2b/3 trial of ritlecitinib, a novel covalent kinase inhibitor targeting JAK3 and TEC kinase family members. The experimental drug demonstrated selectivity in inhibiting signaling molecules and immune cells linked to hair loss in lab experiments. Ritlecitinib represents a promising advancement in alopecia treatment, potentially addressing the underlying mechanisms contributing to hair loss
  • In 2020, Eli Lilly and Company secured FDA breakthrough designation for baricitinib in treating alopecia areata. This designation expedites product development and grants incentives, underscoring the FDA's recognition of the therapy's potential significance in addressing alopecia areata, a condition causing hair loss. The breakthrough status signifies a streamlined regulatory pathway, enabling faster advancements and potential benefits for both the company and patients

Regional Analysis

Geographically, the countries covered in the North America alopecia treatment (hair loss) market report are U.S., Canada and Mexico in North America

As per Data Bridge Market Research analysis:

U.S. is estimated to be the fastest growing country in North America alopecia treatment (hair loss) market during the forecast period 2023-2030

The U.S. is expected to dominate the North America alopecia treatment market due to its highest market share and robust growth rate. The surge is attributed to a rising incidence of male alopecia and continuous advancements in cosmetic procedures for effective treatment. These factors position the U.S. as a key driver in the forecast period, reflecting a heightened demand for innovative solutions in the hair loss treatment landscape.

For more detailed information about the North America alopecia treatment (hair loss) market report, click here – https://www.databridgemarketresearch.com/pt/reports/north-america-alopecia-treatment-hair-loss-market


Client Testimonials